Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?

MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.

ORB-011 by Orionis Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 28, 2023

BioNTech and CEPI partner to develop Mpox vaccine

BioNTech intends to advance a prophylactic mRNA-based Mpox vaccine with an encouraging safety profile that can be produced at scale. Credit: Marcus Krauss/Shutterstock.com. BioNTech has

September 19, 2023

Q&A with Genentech CEO Alexander Hardy on Medicare’s drug price negotiations

Before and after it was acquired by Roche, Genentech has made a name for itself with biologics — the large molecules that Congress recently afforded

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.